市場調查報告書
商品編碼
957990

皰疹標記檢驗的全球市場

Herpes Marker Testing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 272 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球皰疹標記檢驗的市場規模在分析期間(2020年∼2027年)內預計將以4.7%的年複合成長率增長,從2020年的3億2,860萬美元到2027年達到4億5,280萬美元。本報告分析市場區隔之一的病毒培養檢驗部門在分析期間結束前預測將以4.6%的年率增長,達到1億1,120萬美元。

本報告提供全球皰疹標記檢驗市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Laboratories
  • Abcam PLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Meridian Bioscience, Inc.
  • Norgen Biotek Corporation
  • Qiagen NV
  • Quidel Corporation
  • Teco Diagnostics
  • Thermo Fisher Scientific, Inc.

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • Covid-19的影響和即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與成長要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 簡介公司總數:41公司
目錄
Product Code: MCP12352

Abstract:

Global Herpes Marker Testing Market to Reach $452.8 Million by 2027

Amid the COVID-19 crisis, the global market for Herpes Marker Testing estimated at US$328.6 Million in the year 2020, is projected to reach a revised size of US$452.8 Million by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027. Viral Culture Test, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$111.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nucleic Acid Amplification-based Kits segment is readjusted to a revised 5.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $96.8 Million, While China is Forecast to Grow at 4.4% CAGR

The Herpes Marker Testing market in the U.S. is estimated at US$96.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$80.1 Million by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Antibody/Antigen-based Kits Segment to Record 4.2% CAGR

In the global Antibody/Antigen-based Kits segment, USA, Canada, Japan, China and Europe will drive the 4.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$132.6 Million in the year 2020 will reach a projected size of US$177.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$52 Million by the year 2027.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Abcam PLC
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Meridian Bioscience, Inc.
  • Norgen Biotek Corporation
  • Qiagen NV
  • Quidel Corporation
  • Teco Diagnostics
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Viral Culture Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Viral Culture Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Viral Culture Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Nucleic Acid Amplification-based Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Nucleic Acid Amplification-based Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Nucleic Acid Amplification-based Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Antibody/Antigen-based Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Antibody/Antigen-based Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Antibody/Antigen-based Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for HSV-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for HSV-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for HSV-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for HSV-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for HSV-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for HSV-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for HSV-1/HSV-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for HSV-1/HSV-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for HSV-1/HSV-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Research-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Research-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Research-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Academic and Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Academic and Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 40: USA Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 49: USA Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 52: Canada Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 58: Canada Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Canada Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Canada 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 64: Japan Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 67: Japan Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 70: Japan Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Japan Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Japan 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Japan Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Japan 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: China 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 79: China Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: China Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: China 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 82: China Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: China Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: China 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 85: China Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: China Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: China 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 88: Europe Current & Future Analysis for Herpes Marker Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Herpes Marker Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 91: Europe Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Europe Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Europe 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 94: Europe Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Europe Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Europe 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 97: Europe Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Europe Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Europe 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 100: Europe Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 103: France Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: France Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: France 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 106: France Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: France Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: France 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 109: France Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: France Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: France 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 112: France Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: France Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: France 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 115: Germany Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Germany Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Germany 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 118: Germany Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Germany Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Germany 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 121: Germany Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Germany Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Germany 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 124: Germany Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Germany Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Germany 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 127: Italy Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Italy Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Italy 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 130: Italy Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Italy Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Italy 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 133: Italy Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Italy Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Italy 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 136: Italy Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Italy Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Italy 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 139: UK Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: UK Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: UK 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 142: UK Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: UK Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: UK 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 145: UK Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: UK Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: UK 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 148: UK Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: UK Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: UK 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 151: Rest of Europe Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Europe Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Europe 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Europe Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Europe Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Europe 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of Europe Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of Europe Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of Europe 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 160: Rest of Europe Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Rest of Europe Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Rest of Europe 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 163: Asia-Pacific Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Asia-Pacific Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Asia-Pacific 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 166: Asia-Pacific Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Asia-Pacific Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Asia-Pacific 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 169: Asia-Pacific Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Asia-Pacific Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Asia-Pacific 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 172: Asia-Pacific Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Asia-Pacific Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Asia-Pacific 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 175: Rest of World Current & Future Analysis for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Rest of World Historic Review for Herpes Marker Testing by Test Type - Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Rest of World 15-Year Perspective for Herpes Marker Testing by Test Type - Percentage Breakdown of Value Sales for Viral Culture Test, Nucleic Acid Amplification-based Kits and Antibody/Antigen-based Kits for the Years 2012, 2020 & 2027
    • TABLE 178: Rest of World Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Rest of World Historic Review for Herpes Marker Testing by Indication - HSV-1, HSV-2 and HSV-1/HSV-2 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Rest of World 15-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1, HSV-2 and HSV-1/HSV-2 for the Years 2012, 2020 & 2027
    • TABLE 181: Rest of World Current & Future Analysis for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of World Historic Review for Herpes Marker Testing by Application - Research-Use and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of World 15-Year Perspective for Herpes Marker Testing by Application - Percentage Breakdown of Value Sales for Research-Use and Clinical Diagnostics for the Years 2012, 2020 & 2027
    • TABLE 184: Rest of World Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of World Historic Review for Herpes Marker Testing by End-Use - Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of World 15-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Clinics and Academic and Research Institutes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 41